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Purpose: To investigate the feasibility of constant dose rate volumetric modulated arc therapy (CDR-VMAT) in the
treatment of nasopharyngeal cancer (NPC) patients and to introduce rotational arc radiotherapy for linacs incapable
of dose rate variation.
Materials and methods: Twelve NPC patients with various stages treated previously using variable dose rate (VDR)
VMAT were enrolled in this study. CDR-VMAT, VDR-VMAT and mutlicriteria optimization (MCO) VMAT plans were
generated for each patient on RayStation treatment planning system with identical objective functions and the
dosimetric differences among these three planning schemes were evaluated and compared. Non dosimetric
parameters of optimization time, delivery time and delivery accuracy were also evaluated.
Results: The planning target volume of clinical target volume (PTV-CTV) coverage of CDR-VMAT was a bit inferior to
those of VDR- and MCO-VMAT. The V93 (p = 0.01) and V95 (percent volume covered by isodose line) (p = 0.04) for
CDR-VMAT, VDR-VMAT and MCO-VMAT were 98.74% ± 0.31%, 99.76% ± 0.16%, 99.38% ± 0.43%, and 98.40% ± 0.48%,
99.53% ± 0.28%, 99.07% ± 0.52%, respectively. However, the CDR-VMAT showed a better dose homogeneity index
(HI) (p = 0.01) in PTV-CTV. No significant difference in other target coverage parameters was observed. There was no
significant difference in OAR sparing among these three planning schemes except for a higher maximum dose (Dmax)
on the brainstem for CDR-VMAT. The brainstem Dmax of CDR-VMAT, VDR-VMAT and MCO-VMAT were 54.26 ± 3.21 Gy,
52.19 ± 1.65 Gy, and 52.79 ± 4.77 Gy, respectively. The average delivery time (p < 0.01) and the average percent γ
passing rates (p = 0.02) of CDR-VMAT, VDR-VMAT and MCO-VMAT were 7.01 ± 0.43 min, 4.75 ± 0.07 min, 4.01 ± 0.28 min,
and 95.75% ± 2.57%, 97.65% ± 1.45%, 97.36% ± 2.45%, respectively.
Conclusion: CDR-VMAT offers an additional option of rotational arc radiotherapy for linacs incapable of dose rate
variation with a lower initial cost. Its plan quality was acceptable but should be thoroughly checked compared
with VDR-VMAT and MCO-VMAT in the treatment of NPC.
Keywords: Volumetric-modulated arc therapy, Constant dose rate, Variable dose rate, Multicriteria optimization,
Nasopharyngeal cancerIntroduction
Due to its dose painting ability, intensity-modulated
radiation therapy (IMRT), which is able to deliver more
conformal radiation to the tumor than earlier techniques
and spare the surrounding normal tissue from un-
necessary exposure [1], has been accepted as a standard
treatment modality for nasopharyngeal cancer (NPC) [2].* Correspondence: physics@wzhospital.cn
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unless otherwise stated.Disadvantages of IMRT are the longer required irradiation
time and the greater total number of monitor units (MUs)
compared with conventional methods [1]. The increased
irradiation time may increase the intrafractional error
and the patient restriction time. Additionally, an in-
crease in the total number of MUs may expose the pa-
tients to the risk of low-dose irradiation owing to
increased leakage [3].
More recently, volumetric-modulated arc therapy
(VMAT), an extended form of IMRT using a variable dose
rate (VDR), dynamic gantry speed and multileaf collimator
(MLC) field shape, has gained considerable attention [4].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Yu et al. Radiation Oncology 2014, 9:235 Page 2 of 7
http://www.ro-journal.com/content/9/1/235VMAT plans with shorter delivery time, fewer MU,
and superior or equivalent plan quality compared to
conventional step-and-shoot IMRT have been reported
for prostate cancer and NPC [5,6]. However, to use the
VMAT approach, the hardware and software systems
of the radiation treatment planning system (TPS), as
well as the linear accelerator (linac), must be upgraded.
These upgrades are costly. Thus, many institutions do not
have the means to perform VMAT and must continue
with the problems specified above. Constant dose rate
(CDR) VMAT is a rotational IMRT technique that uses a
fixed gantry rotational speed and a fixed dose rate. Com-
pared with fixed field IMRT, the potential advantages of
CDR with a great reduction in irradiation time and clinical
acceptable dose distribution has been reported [5,7]. For
institutions that do not currently perform VDR-VMAT,
CDR-VMAT may be a useful option.
Multicriteria optimization (MCO) with multipareto
fronts has emerged as a tool for comparing treatment
plans as it gives better visualization of the trade-offs
[8-10]. MCO allows trade-offs between conflicting ob-
jectives encountered in VMAT planning to be explored
in an interactive manner through search over a continu-
ous representation of the relevant treatment options.
MCO-VMAT plans in the treatment of prostate, pancreas,
lung, and head and neck cancer patients have been re-
ported with comparable dose distribution quality to con-
ventionally optimized VMAT plans [11]. During the MCO
optimization process, despite protocols, the final choice of
the best solution will be planner dependent. However, in
comparing Pareto fronts for different techniques, a bias
towards planner experience can be minimized.
NPC is the most common H&N malignancy in Southeast
Asia and China. The newly VDR-VMAT is an ideal
treatment technique in NPC treatment but cost too
much in linac upgrading. The purpose of this study is to
investigate the dosimetric differences among CDR-VMAT,
VDR-VMAT and MCO-VMAT and the feasibility of
CDR-VMAT in the treatment of NPC patients.
Materials and methods
Patients and contours
Twelve patients with various stages of NPC treated pre-
viously by VDR-VMAT were enrolled in this study. All
VDR-VMAT plans with initial CT data were exported
from the Pinnacle TPS to the Raystation TPS (clinical
version 3.5, RaySearch Laboratories, Stockholm, Sweden)
through the DICOM service and the dose distributions
were recalcuated based on the same CT number to dens-
ity calibration curve using a collapsed cone dose engine
with a dose grid of 4 mm× 4 mm× 4 mm. CDR-VMAT,
VDR-VMAT and MCO-VMAT plans were generated for
each patient on the RayStation TPS. The Raystation
TPS was commissioned with the same beam data as thePinnacle system. The dose deviations between Raystation
and Pinnacle were within 1.5% during the commission
process. Dosimetric differences among these three plan-
ning methods were compared.
Target and normal tissue contours have been reported
in our previous study and are generalized here [12]. Gross
tumor volume (GTV) was delineated as the mass shown
in the enhanced computed tomography images or mag-
netic resonance images or both. The clinical target volume
(CTV) was defined as the GTV plus a margin of potential
microscopic spread. One typical contour is shown in
Figure 1. The planning target volume (PTV) was created
by adding a 3 mm margin to the CTV account for setup
variability. In order to increase the coverage of the
GTV, a PTV-GTV was generated by adding a 2 mm
margin to the GTV. Organ at risks (OARs) (brain stem,
spinal cord, lens, left and right parotids) were contoured
and constrained for optimization.
Treatment planning
The prescription doses to PTV-GTV and PTV-CTV were
2.5 Gy and 2.0 Gy per fraction for a total dose of 70 Gy and
56 Gy in 28 fractions with simultaneous integrated boost
(SIB), respectively. VDR-VMAT objective settings were
employed in the optimization for all plans as shown in
Table 1. The optimization parameters of VDR-VMAT have
been reported in our previous study and are summarized
briefly here [6]. Leaf motion constraints of 0.46 cm/deg and
a final arc spacing of 4 degree were employed. A start angle
of 181 degree and a stop angle of 180 degree were applied
for the first arc in a clockwise direction. The second arc
rotated counterclockwise from 181 to 180 degree. For
CDR-VMAT plans, a fixed dose rate of 400 MU/minute
was selected. The collimator was set to 45 degree for all
VMAT plans to reduce the cumulative effects of interleaf
transmission and the tongue and groove effect. Other set-
tings (like leaf motion, beam numbers and beam rotation)
of CDR-VMAT were the same as the VDR-VMAT.
For MCO optimization, the Pareto surface was approxi-
mated by using N +1 treatment plans, where N is the
number of objectives. N of the plans are from each of the
objectives being minimized individually. The additional
plan is a balanced plan formed by optimizing the equal
weighted sum of all objectives. A senior physician will
navigating the base plans and decided the best plan. When
navigation is completed, the Raystation TPS will create a
deliverable version of the selected plan by a direct aper-
ture optimization algorithm using a total of 50 segments
as VDR-VMAT and CDR-VMAT to match the navigated
DVH.
Plan evaluation and comparison
The dose distributions delivered by the three modalities
were compared by evaluating target coverage (TC) and
Figure 1 Typical target contours for nasopharyngeal cancer patients, green for CTV, red for GTV, pink for right parotid, sky blue for
left parotid, and yellow for spinal cord.
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dose (Dmin), mean dose (Dmean), the volumes receiving
93% (V93) and 95% (V95) of the prescribed dose of
PTV-GTV and PTV-CTV; the Dmax of brainstem, spinal
cord, lens, and the Dmean of parotids were evaluated and
compared. For parotids, the percent volume of each par-
otid that received 26 Gy (V26), and 32 Gy (V32) was also
evaluated and compared. Additional quality indices were
calculated for further evaluation and comparison as listed
in the following paragraphs.
The homogeneity index (HI) was evaluated as the
difference between the dose to 1% (D1) and 99% (D99)
of PTV divided by the prescription dose (Dp) [13]HI ¼ D1−D99
Dp
 100% ð1Þ
Conformity index (CI) [14] and conformation number
(CN) [15] were also calculated for the PTV as








Where VT,Pi is the volume of the target that is covered
by the prescription dose, VT is the target volume. VPi is
Table 1 Objective setting and weight for inverse
optimization
ROI Type Target(cGy) % Volume Weight
PTV-GTV Min Dose 6930 20
PTV-GTV Uniform Dose 7000 10
PTV-GTV Max Dose 7700 10
PTV-CTV Min Dose 5544 20
PTV-CTV Uniform Dose 5600 10
PTV-CTV Max Dose 6160 10
Brainstem Max Dose 5000 1
Cord Max Dose 4000 1
R parotid Max EUD A1 2600 40 1
L parotid Max EUD A1 2600 40 1
lens Max Dose 700 1
1 cm Ring out CTV Max DVH 5600 10 1
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isodose. The maximum value of the CI is 1, corresponding
to a perfect coverage of the PTV. The CN is the comple-
mentary information to compensate for the defects of
target coverage and CI. The CN can take values between
0 and 1, where an ideal dose distribution would have a
CN value of 1.
The VMAT plans were verified by an ArcCheck phan-
tom and the SNCP Patient analysis software (Version 6,
Sun Nuclear Corporation, Melbourne, FL) with a gamma
criterion of 3%/ 3 mm. For profile analysis, a threshold
dose of 10% of the maximum dose was used. All plans
were delivered on an Elekta Synergy linac (Elekta Ltd.,
Crawley, UK) with a MOSAIQ record and verify system
(version 1.60Q3, IMPAC Medical Systems, Inc.,Sunnyvale,
CA). Besides, the optimization time, MU efficiency, and
delivery time were compared.Table 2 Patients characteristics
Patients no. Staging Gender Age
1 T2N2MX M 48
2 T2N1MX M 63
3 T3N0M0 M 71
4 T4N0MX M 59
5 T3N3MX M 71
6 T2N2MX F 66
7 T4N0MX M 55
8 T2N2MX M 39
9 T2N3MX M 48
10 T1N1M0 M 62
11 T2bN1M0 F 55
12 T2bN2M0 F 65Statistical analysis
The differences among the three planning schemes
were analyzed using one-way ANOVA. When an
overall significant difference was observed, the post
hoc Turkey’s test was used to determine which
pair-wise comparisons differed. All statistical ana-
lyses were conducted with the SPSS 17.0 software.
Differences were considered statistically significant for
p <0.05.
Results
A total of 36 VMAT plans were generated for 12 NPC
patients (3 female and 9 male) with an average age of
58.5 years (48–71). Table 2 lists the clinical character-
istics of these 12 patients. The average PTV-GTV and
PTV-CTV volumes were 82.1 cm3 (59.6-171.0) and
594.1 cm3 (416.5-757.7), respectively.
Figure 2 shows a typical DVH comparison for one
patient among these three planning schemes. For
this particular patient, a similar PTV-GTV coverage
is observed with less hotspot in CDR-VMAT. The
PTV-CTV coverage of MCO-VMAT was better as
compared with the other two planning schemes. VDR-
VMAT presented a better sparing of the spinal cord
and brainstem and CDR-VMAT showed the worst lens
protection compared with the other two schemes.
Table 3 presents the detailed statistical analysis of
target coverage for all the patients. No significant
difference in PTV-GTV coverage was shown. The V93
(p = 0.01) and V95 (p = 0.04) of PTV-CTV for CDR-VMAT,
VDR-VMAT and MCO-VMAT were 98.74% ± 0.31%,
99.76% ± 0.16%, 99.38% ± 0.43%, and 98.40% ± 0.48%,
99.53% ± 0.28%, 99.07% ± 0.52%, respectively. The HIs
for CDR-VMAT, VDR-VMAT and MCO-VMAT were
0.28 ± 0.017,0.29 ± 0.012, 0.31 ± 0.023, respectively (p = 0.01).













Figure 2 DVH comparison among CDR-VMAT, VDR-VMAT and MCO-VMAT for one NPC patient.
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other two planning schemes. No significant difference
in other target coverage parameters was observed.
The comparison of OAR sparing is presented in Table 4.
The average Dmax of the brainstem for CDR-VMAT, VDR-
VMAT and MCO-VMAT was 54.26 ± 3.21 Gy, 52.19 ±
1.65 Gy, and52.79 ± 4.77 Gy, respectively (p = 0.01). The
average Dmax of the brainstem of CDR-VMAT was higherTable 3 Target coverage comparison
CDR-VMAT VDR-VMAT MCO-VMAT p
PTV-GTV
Dmean (Gy) 68.41 ± 1.21 68.71 ± 1.28 68.34 ± 0.47 0.42
Dmax (Gy) 71.02 ± 0.93 70.66 ± 1.29 70.44 ± 0.63 0.55
V93 (%) 99.91 ± 0.18 99.93 ± 0.04 99.98 ± 0.02 0.31
V95 (%) 99.72 ± 0.38 99.69 ± 0.13 99.83 ± 0.16 0.38
HI 0.11 ± 0.021 0.12 ± 0.016 0.11 ± 0.026 0.33
CI 0.62 ± 0.64 0.57 ± 0.10 0.65 ± 0.06 0.43
CN 0.62 ± 0.44 0.56 ± 0.11 0.63 ± 0.05 0.26
PTV-CTV
Dmean (Gy) 56.65 ± 0.47 57.50 ± 1.08 56.15 ± 0.62 1.13
Dmax (Gy) 70.09 ± 0.83 70.76 ± 1.06 70.57 ± 0.43 0.62
V93 (%) 98.74 ± 0.31 99.76 ± 0.16 99.38 ± 0.43 0.01
V95 (%) 98.40 ± 0.48 99.53 ± 0.28 99.07 ± 0.52 0.04
HI 0.28 ± 0.017 0.29 ± 0.012 0.31 ± 0.023 0.01
CI 0.58 ± 0.14 0.57 ± 0.10 0.60 ± 0.06 0.06
CN 0.58 ± 0.04 0.56 ± 0.12 0.57 ± 0.15 0.12(p = 0.02) than the other two methods. No significant dif-
ference in other OAR parameters was observed among
these three planning schemes. For non dosimetric param-
eter comparisons, the average MU values of CDR-VMAT,
VDR-VMAT and MCO-VMAT were 544.88 ± 106.95,
565.88 ± 25.34, 526.38 ± 54.38, respectively (p = 0.06).
The average delivery times of CDR-VMAT, VDR-VMAT
and MCO-VMAT were 7.01 ± 0.43 min, 4.75 ± 0.07 min,
4.01 ± 0.28 min, respectively (p < 0.01). The average per-
cent γpassing rates were 95.75% ± 2.57%, 97.65% ± 1.45%,Table 4 OAR sparing comparison
CDR-VMAT VDR-VMAT MCO-VMAT p
Brainstem
Dmax (Gy) 54.26 ± 3.21 52.19 ± 1.65 52.79 ± 4.77 0.01
Cord
Dmax(Gy) 45.12 ± 4.94 44.59 ± 2.10 44.11 ± 4.37 0.47
Left parotid
Dmean (Gy) 29.72 ± 1.48 28.42 ± 1.75 28.46 ± 2.70 0.93
V26 (%) 53.84 ± 4.41 50.55 ± 3.75 49.73 ± 8.82 0.34
V32 (%) 34.36 ± 5.50 33.22 ± 5.28 33.01 ± 9.33 0.16
V50 (%) 6.44 ± 5.05 6.55 ± 5.65 5.72 ± 4.58 0.68
Right parotid
Dmean (Gy) 29.79 ± 1.73 28.76 ± 1.15 28.6 ± 2.18 0.98
V26 (%) 48.04 ± 3.90 47.38 ± 3.75 48.45 ± 7.99 0.42
V32 (%) 31.78 ± 5.80 30.22 ± 5.35 30.84 ± 8.28 0.30
V50 (%) 7.07 ± 3.81 6.17 ± 3.93 6.26 ± 3.34 0.45
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optimization time of CDR-VMAT (24.74 ± 1.06 min)
was shorter than VDR-VMAT (40.8 ± 4.83 min). The
optimization time of MCO-VMAT was short (5.36 ±
2.55 min), but it took a long and variable navigation
time, which is about 40 minutes.
Discussion
This study has investigated the dosimetric differences
among CDR-VMAT, VDR-VMAT and MCO-VMAT in
the treatment of NPC patients and the feasibility of
CDR-VMAT. Dual arc CDR-VMAT is able to achieve
acceptable target coverage and OAR sparing compared
with VDR-VMAT and MCO-VMAT in the treatment of
NPC patients.
Due to the limited availability of linacs with reliable
variable dose rate capability, CDR-VMAT has been inves-
tigated in order to deliver rotational arcs using a constant
dose-rate with a lower initial cost compared with VDR-
VMAT [16]. In this study, CDR-VMAT achieves a similar
target coverage, dose homogeneity and conformity of
the PTV-GTV compared with VDR-VMAT and MCO-
VMAT. However, CDR-VMAT was a bit inferior on the
coverage on PTV-CTV and superior in dose homogeneity.
Similar results have been reported, showing that the dif-
ferences in the GTV and PTV coverage for head-and-neck
cancer patients (dose received by 95% of GTV or PTV) in
the VDR- and CDR-VMAT plans were within 0.1% [17].
The maximum dose to the brainstem for CDR-VMAT
was a bit higher compared with the other two planning
schemes, but it was still within the clinical tolerance.
There was no other significant difference on OAR sparing
among these three VMAT planning schemes.
MCO with a pareto surface-based technique has been
demonstrated as a method to efficiently explore tradeoffs
between different treatment goals in the irradiation of
various tumors. Treatment plans selected from such a
representation are of comparable dose distribution quality
to conventionally optimized VMAT plans [11]. In this
study, consistent results were observed with equivalent
dose distribution for MCO-VMAT and VDR-VMAT in
the treatment of NPC. The equivalent dosimetric distribu-
tion of CDR-VAMT was further verified by MCO-VMAT
in this study.
The delivery efficiency and MU reduction are some of
the features that VMAT was favored over conventional
fixed field IMRT. The average delivery time of CDR-VMAT
was longer than VDR-VMAT (7.01 ± 0.43 min vs. 4.75 ±
0.07 min), but it was still much shorter than that of IMRT
(11.01 ± 0.43 min) as reported in our previous study [6].
All the CDR-VMAT plans were delivered smoothly and
accurately in this study with an average percent γpassing
rate of 95.75% ± 2.57%. This is consistent with the study of
Tang et al. [17]VDR-VMAT both with single arc and dual arc has
been widely investigated in the treatment of various
tumor sites with superior or equivalent dose distribution
and reduced delivery time and MUs [5,6,18]. However,
the VDR-VMAT capability is not available for the low- or
intermediate-end linacs without upgrade in institutions
especially in the underdeveloped countries and regions. A
careful study in the dosimetric distribution and feasibility
of CDR-VMAT in such institutions will be of clinical
benefit for both hospitals and patients.
Conclusion
CDR-VMAT offers an additional option of rotational arc
radiotherapy for linacs incapable of dose rate variation
with a lower initial cost. Its plan quality is acceptable but
should be checked with care compared to VDR-VMAT
and MCO-VMAT in the treatment NPC.
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